Patent ID: 9278124
Filing Date: 2016-03-08
CPC Classification: A61K,G01N

Claim Text:
1. A method of treating a subject having a hypoxia-related disease or condition, comprising: a) measuring the level or amount of hyaluronan (HA) in a sample from a subject, whereby if the HA is at or above a predetermined level, the subject is susceptible to treatment with a hypoxia-activated agent, wherein: the HA is measured by detecting binding of a HA-binding protein (HABP) to the sample, and the HABP comprises a Tumor necrosis factor-Stimulated Gene-6 (TSG-6) link module (LM) or a sufficient portion thereof that specifically binds to HA; b) selecting a susceptible subject for treatment with a hyaluronidase and a hypoxia-activated agent; and c) administering a soluble hyaluronidase and a therapeutically effective amount of a hypoxia-activated agent to the subject, wherein the soluble hyaluronidase and the hypoxia-activated agent are administered simultaneously, sequentially or intermittently in any order, to thereby treat the subject.